Critical Reviews in Therapeutic Drug Carrier Systems最新文献_第3页

A Review on Recent Advances in Mannose-Functionalized Targeted Nanocarrier Delivery Systems in Cancer and Infective Therapeutics. 甘露糖功能化靶向纳米载体递送系统在癌症和感染治疗中的最新进展。

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2022041853

Vasanti Suvarna, Niserga Sawant, Namita Desai

{"title":"A Review on Recent Advances in Mannose-Functionalized Targeted Nanocarrier Delivery Systems in Cancer and Infective Therapeutics.","authors":"Vasanti Suvarna, Niserga Sawant, Namita Desai","doi":"10.1615/CritRevTherDrugCarrierSyst.2022041853","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2022041853","url":null,"abstract":"Unmodified nanocarriers used in the chemotherapy of cancers and various infectious diseases exhibit prolonged blood circulation time, prevent enzymatic degradation and increase chemical stability of encapsulated therapeutics. However, off-target effect and lack of specificity associated with unmodified nanoparticles (NPs) limit their applications in the health care system. Mannose (Man) receptors with significant overexpression on antigen-presenting cells and macrophages are among the most admired targets for cancer and anti-infective therapeutics. Therefore, development of Man functionalized nanocarriers targeting Man receptors, for target specific drug delivery in the chemotherapy have been extensively studied. Present review expounds diverse Man-conjugated NPs with their potential for targeted drug delivery, improved biodistribution profiles and localization. Additionally, the review gives detailed account of the interactions of mannosylated NPs with various biological systems and their characterization not discussed in earlier published reports is discussed.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 2","pages":"43-82"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9228684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Recent Advances and Prospects for Plant Gum-Based Drug Delivery Systems: A Comprehensive Review. 植物胶基给药系统的研究进展与展望

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2022042252

Minkal Tuteja, Kalpana Nagpal

引用次数: 0

Nanotherapeutic Approach to Delivery of Chemo- and Gene Therapy for Organ-Confined and Advanced Castration-Resistant Prostate Cancer. 用纳米治疗方法为器官封闭的晚期阉割耐药前列腺癌提供化疗和基因治疗。

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2022043827

Satish Sharma, Supriya D Mahajan, Kent Chevli, Stanley A Schwartz, Ravikumar Aalinkeel

{"title":"Nanotherapeutic Approach to Delivery of Chemo- and Gene Therapy for Organ-Confined and Advanced Castration-Resistant Prostate Cancer.","authors":"Satish Sharma, Supriya D Mahajan, Kent Chevli, Stanley A Schwartz, Ravikumar Aalinkeel","doi":"10.1615/CritRevTherDrugCarrierSyst.2022043827","DOIUrl":"10.1615/CritRevTherDrugCarrierSyst.2022043827","url":null,"abstract":"Treatments for late-stage prostate cancer (CaP) have not been very successful. Frequently, advanced CaP progresses to castration-resistant prostate cancer (CRPC), with 50#37;-70% of patients developing bone metastases. CaP with bone metastasis-associated clinical complications and treatment resistance presents major clinical challenges. Recent advances in the formulation of clinically applicable nanoparticles (NPs) have attracted attention in the fields of medicine and pharmacology with applications to cancer and infectious and neurological diseases. NPs have been rendered biocompatible, pose little to no toxicity to healthy cells and tissues, and are engineered to carry large therapeutic payloads, including chemo- and genetic therapies. Additionally, if required, targeting specificity can be achieved by chemically coupling aptamers, unique peptide ligands, or monoclonal antibodies to the surface of NPs. Encapsulating toxic drugs within NPs and delivering them specifically to their cellular targets overcomes the problem of systemic toxicity. Encapsulating highly labile genetic therapeutics such as RNA within NPs provides a protective environment for the payload during parenteral administration. The loading efficiencies of NPs have been maximized while the controlled their therapeutic cargos has been released. Theranostic (\"treat and see\") NPs have developed combining therapy with imaging capabilities to provide real-time, image-guided monitoring of the delivery of their therapeutic payloads. All of these NP accomplishments have been applied to the nanotherapy of late-stage CaP, offering a new opportunity for a previously dismal prognosis. This article gives an update on current developments in the use of nanotechnology for treating late-stage, castration-resistant CaP.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 4","pages":"69-100"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11007628/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9475172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in Current Drugs and Formulations for the Management of Atopic Dermatitis. 目前治疗特应性皮炎的药物及配方研究进展。

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2023042979

Keerthi Atluri, Srikanth Manne, Vijendra Nalamothu, Alon Mantel, Purnendu K Sharma, R Jayachandra Babu

{"title":"Advances in Current Drugs and Formulations for the Management of Atopic Dermatitis.","authors":"Keerthi Atluri, Srikanth Manne, Vijendra Nalamothu, Alon Mantel, Purnendu K Sharma, R Jayachandra Babu","doi":"10.1615/CritRevTherDrugCarrierSyst.2023042979","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2023042979","url":null,"abstract":"Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease with a complex pathophysiology. Treatment of AD remains challenging owing to the presence of a wide spectrum of clinical phenotypes and limited response to existing therapies. However, recent genetic, immunological, and pathophysiological insights into the disease mechanism resulted in the invention of novel therapeutic drug candidates. This review provides a comprehensive overview of current therapies and assesses various novel drug delivery strategies currently under clinical investigation. Further, this review majorly emphasizes on various topical treatments including emollient therapies, barrier repair agents, topical corticosteroids (TCS), phosphodiesterase 4 (PDE4) inhibitors, calcineurin inhibitors, and Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway inhibitors. It also discusses biological and systemic therapies, upcoming treatments based on ongoing clinical trials. Additionally, this review scrutinized the use of pharmaceutical inactive ingredients in the approved topical dosage forms for AD treatment.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 6","pages":"1-87"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10010645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent Advances in Teriparatide Delivery by-virtue-of Novel Drug Delivery Approaches for the Management of Osteoporosis. 特立帕肽在骨质疏松症治疗中的新给药途径研究进展。

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2023045014

Sagar Salave, Dhwani Rana, Kedar Prayag, Srushti Shah, Garima Rawat, Nitish Sharma, Anil B Jindal, Rikin Patel, Derajram Benival

{"title":"Recent Advances in Teriparatide Delivery by-virtue-of Novel Drug Delivery Approaches for the Management of Osteoporosis.","authors":"Sagar Salave, Dhwani Rana, Kedar Prayag, Srushti Shah, Garima Rawat, Nitish Sharma, Anil B Jindal, Rikin Patel, Derajram Benival","doi":"10.1615/CritRevTherDrugCarrierSyst.2023045014","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2023045014","url":null,"abstract":"Osteoporosis is a bone incapacitating malady which globally accounts for over hundred million fractures annually. Therapeutic interventions for management of osteoporosis are divided as antiresorptive agents and osteoanabolic agents. Teriparatide is the only osteoana-bolic peptide which is available world-wide for the treatment of osteoporosis. It is administered as a daily subcutaneous injection for the treatment of osteoporosis which results in both poor patient compliance and increase in the cost of the therapy. Even after 20 years of clinical use of teriparatide, no formulation of teriparatide has yet been translated from lab to clinic which can be delivered by non-invasive route The present review critically discusses attempts made by the researchers for efficient delivery of teriparatide through various non-invasive routes such as oral, nasal, pulmonary, and transdermal route. It also discusses long-acting injectable formulations of teriparatide to improve patient compliance. Understanding on the pharmacology of teriparatide highlights the enhanced effectiveness of intermittent/pulsatile mode of teriparatide delivery which has also been elaborated. In addition, targeted delivery of teriparatide using different bone specific targeting moieties has been also discussed.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 5","pages":"93-123"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9898040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Overview on Macrophage Targeting: A Promising Approach. 巨噬细胞靶向研究综述:一个有前途的方法。

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2022038827

Venkata Deepthi Vemuri, Rekharani Kushwaha, Gollu Gowri, Nalini Mathala, Swathi Nalla, Sasikala Allam, Gurijala Lekhya

{"title":"An Overview on Macrophage Targeting: A Promising Approach.","authors":"Venkata Deepthi Vemuri, Rekharani Kushwaha, Gollu Gowri, Nalini Mathala, Swathi Nalla, Sasikala Allam, Gurijala Lekhya","doi":"10.1615/CritRevTherDrugCarrierSyst.2022038827","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2022038827","url":null,"abstract":"Macrophages are immuno cells with high flexibility among hematopoietic system. Macrophages are tangled with many diseases like chronic inflammatory, atherosclerosis, autoimmune, and cancer. Macrophages play a major role in developing the inflammation and meanwhile resolving the damage occurred during these disease conditions. Therefore, the use of macrophages in targeted drug delivery appeared to be a promising approach in modifying the microenvironment of inflammatory diseases. The macrophages with cellular backpacks loaded with drugs were appeared to be the effective drug transporter to the brain inflammation. Till date, among the different carrier systems emerged among macrophage targeting: liposomes, microspheres, nanoparticles, and dendrimers were extensively studied. The physicochemical properties like components, lipophilicity, hydrophilicity, ligand presence, and concentration of these carriers may vary the efficacy and specificity of drug targeting to macrophages. The present review provides an insight into M1 and M2 macrophages characteristics, mainly discussed the role of macrophages in regulating several inflammatory diseases. This article underlines the current status and application of different carriers for targeted drug delivery to macrophages along with their efficacy and specificity. In general, the targeted drug delivery was achieved using the carrier systems by removing the intrinsic pathway and bio protection which is offered to the therapeutic molecules. Further, the review also summarizes the newer approaches for macrophage targeting with a brief overview on recent advances and future prospects.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 5","pages":"47-92"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9901988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cyclodextrin-Based Arsenal for Anti-Cancer Treatments. 基于环糊精的抗癌药物库。

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2022038398

Hitesh Chopra, Ravinder Verma, Sakshi Kaushik, Jatin Parashar, Kumud Madan, Afsareen Bano, Rashmi Bhardwaj, Parijat Pandey, Beena Kumari, Deepika Purohit, Manish Kumar, Saurabh Bhatia, Md Habibur Rahman, Vineet Mittal, Inderbir Singh, Deepak Kaushik

{"title":"Cyclodextrin-Based Arsenal for Anti-Cancer Treatments.","authors":"Hitesh Chopra, Ravinder Verma, Sakshi Kaushik, Jatin Parashar, Kumud Madan, Afsareen Bano, Rashmi Bhardwaj, Parijat Pandey, Beena Kumari, Deepika Purohit, Manish Kumar, Saurabh Bhatia, Md Habibur Rahman, Vineet Mittal, Inderbir Singh, Deepak Kaushik","doi":"10.1615/CritRevTherDrugCarrierSyst.2022038398","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2022038398","url":null,"abstract":"Anti-cancer drugs are mostly limited in their use due to poor physicochemical and biopharmaceutical properties. Their lower solubility is the most common hurdle limiting their use upto their potential. In the recent years, the cyclodextrin (CD) complexation have emerged as existing approach to overcome the problem of poor solubility. CD-based nano-technological approaches are safe, stable and showed well in vivo tolerance and greater payload for encapsulation of hydrophobic drugs for the targeted delivery. They are generally chosen due to their ability to get self-assembled to form liposomes, nanoparticles, micelles and nano-sponges etc. This review paper describes a birds-eye view of the various CD-based nano-technological approaches applied for the delivery of anti-cancer moieties to the desired target such as CD based liposomes, niosomes, niosoponges, micelles, nanoparticles, monoclonal antibody, magnetic nanoparticles, small interfering RNA, nanorods, miscellaneous formulation of anti-cancer drugs containing CD. Moreover, the author also summarizes the various shortcomings of such a system and their way ahead.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 2","pages":"1-41"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9228678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implementation of Quality by Design in the Formulation and Development of Nanocarrier-Based Drug Delivery Systems. 设计质量在纳米载体给药系统的处方和开发中的实施。

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2022042927

Sonal Mehrotra, A Salwa, Lalit Kumar

{"title":"Implementation of Quality by Design in the Formulation and Development of Nanocarrier-Based Drug Delivery Systems.","authors":"Sonal Mehrotra, A Salwa, Lalit Kumar","doi":"10.1615/CritRevTherDrugCarrierSyst.2022042927","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2022042927","url":null,"abstract":"Quality by design (QbD) has recently fascinated researchers for utilizing it in various arenas of pharma trends. By overcoming the conventional process, QbD prevents the risk of errors caused by the 'guess and by god approach'. This framework fosters profound knowledge of product and process quality by implying sound science and risk assessment strategies. The virtue of QbD leads to the collaborative contribution to pharmaceutical industrialists and satisfies the regulatory bodies. Additionally, leading to rapid production, saves time and expenditure, tremendous versatility, provides immense knowledge, improves robustness, higher consistency, reduces user's dilemma, decreases certainty of failure, declining inter-batch variation in pharmaceutical development. In this ever-increasing continuous production world, regulatory organizations such as the U.S. Food & Drug Administration and the International Conference on Harmonization recommend Q8 to Q14 guidelines in order to obtain the desired quality product. This review extensively discusses on various approaches of QbD for the pharmaceutical development of nano-carrier drug delivery systems. Additionally, QbD's applications in process and analytical method development techniques are documented.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 3","pages":"1-46"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9228613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting pathways and integrated approaches to treat Rheumatoid Arthritis 治疗类风湿关节炎的靶向途径和综合方法

4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2023-01-01 DOI: 10.1615/critrevtherdrugcarriersyst.2023044719

Shradha Devi Dwivedi, Krishna Yadav, Anita Bhoi, Keshav Kant Sahu, Neelam Sangwan, Deependra Singh, Manju Singh

{"title":"Targeting pathways and integrated approaches to treat Rheumatoid Arthritis","authors":"Shradha Devi Dwivedi, Krishna Yadav, Anita Bhoi, Keshav Kant Sahu, Neelam Sangwan, Deependra Singh, Manju Singh","doi":"10.1615/critrevtherdrugcarriersyst.2023044719","DOIUrl":"https://doi.org/10.1615/critrevtherdrugcarriersyst.2023044719","url":null,"abstract":"Rheumatoid arthritis (RA) is a chronic symmetrical systemic disorder that not only affects joints but also other organs such as heart, lungs, kidney, and liver. Approximately there is 0.5% -1% of the total population affected by rheumatoid arthritis. RA pathogenesis still remains unclear due to which its appropriate treatment is a challenge. Further, multitudes of factors have been reported to affect its progression i.e. genetic factor, environmental factor, immune factor, and oxidative factor. Therapeutic approaches available for the treatment of RA include NSAIDs, DMARDs, enzymatic, hormonal, and gene therapies. But most of them provide the symptomatic relief without treating the core of the disease. This makes it obligatory to explore and reach the molecular targets for cure and long term relief from rheumatoid arthritis. Herein, we attempt to provide extensive overlay of the new targets for RA treatment such as signalling pathways, proteins, and receptors affecting the progression of the disease and its severity. Precise modification in these targets such as suppressing the notch signalling pathway, SIRT 3 protein, Sphingosine-1-phosphate receptor and stimulating the neuronal signals particularly efferent vagus nerve and SIRT 1 protein may offer long term relief and potentially diminish the chronicity. To target or alter the novel molecules and signaling pathway a specific delivery system is required such as liposome, nanoparticles and micelles and many more. In these review paper we have discuss about novel targets and delivery system for treating RA.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"119 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135612283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Self-Assembly Polymeric Nano Micelles for the Futuristic Treatment of Skin Cancer and Phototoxicity: Therapeutic and Clinical Advancement. 自组装聚合物纳米胶束用于皮肤癌和光毒性的未来治疗:治疗和临床进展。

IF 2.7 4区医学

Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2022-01-01 DOI: 10.1615/critrevtherdrugcarriersyst.2021035589

N. Mehan, Manish Kumar, S. Bhatt, R. Shankar, B. Kumari, R. Pahwa, Deepak Kaushik

{"title":"Self-Assembly Polymeric Nano Micelles for the Futuristic Treatment of Skin Cancer and Phototoxicity: Therapeutic and Clinical Advancement.","authors":"N. Mehan, Manish Kumar, S. Bhatt, R. Shankar, B. Kumari, R. Pahwa, Deepak Kaushik","doi":"10.1615/critrevtherdrugcarriersyst.2021035589","DOIUrl":"https://doi.org/10.1615/critrevtherdrugcarriersyst.2021035589","url":null,"abstract":"In the last few years, the polymeric micelles played a major role as a drug carrier in nano-sized drug delivery system. The polymeric micelles are designed from synthetic block co-polymers and graft copolymers. In the mixed micelles, the bilayer lipid membrane and surfactants are used. Both micelles are in nano-sized and used to enhance the drug delivery to treat different diseases. In this review, we will discuss some examples from the literature included demonstrating the polymeric micelles used as drug-carriers in skin cancer treatment by using different drugs. We also summarized mixed micelles, polymeric micelles in skin drug delivery, various polymers, and techniques of polymeric micelles. These micelles may improve delivery of drug in the skin's targeted sites in specific and dermatological diseases like skin cancer, acne, and fungal infection. In the comparison of surfactant micelles, the polymeric micelles are more stable. Polymeric micelles act as a colloidal carrier for incorporating poorly water-soluble and amphiphilic drugs.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"39 2 1","pages":"79-95"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67437705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7